Phase 1 Study(Additional) of URC102 in Healthy Subjects

A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males

The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.

Tolerability, safety, and pharmacokinetics (PK) of URC102 will be assessed after 7-day repeated oral dose in healthy adult Korean males. In addition, pharmacodynamic (PD) response of blood and urinary uric acid levels will be assessed.

Inclusion Criteria:

• Healthy male volunteers

Exclusion Criteria:

• Participated in other clinical study within past 3 months prior to receiving an IP administration